Search Results

RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product™ for Diabetic Foot Ulcers

RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™).

May 7, 2024

·

5 min read

BioMidwest

Rion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rion today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM.

January 2, 2024

·

1 min read

Drug Development

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).

January 30, 2024

·

6 min read

BioMidwest

RION, Mayo Clinic, and the U.S. Army Medical Research Institute for Chemical Defense Receive $2.4M Department of Defense Award to Advance Exosome-Based Research in Pulmonary Therapeutics

RION, a leading clinical-stage regenerative medicine company, announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense on a $2.4M grant awarded from the Department of Defense.

November 20, 2023

·

3 min read

Business

RION Announces the Advisory Appointments of John Ballantyne, Ph.D., to Chair of the Rion Scientific Advisory Board and Andrew D. Badley, M.D., to Chair of the Rion Medical Advisory Board

RION, a clinical-stage regenerative medicine company with breakthrough platform technology leveraging platelet-derived exosomes, announces the appointment of Dr. Ballantyne as Chair of the company’s Scientific Advisory Board and Dr. Andrew D. Badley as Chair of the Rion Medical Advisory Board.

January 25, 2023

·

4 min read

Business

RION Appoints Alisa Lask as Chief Commercial Officer

RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer.

January 14, 2022

·

2 min read

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be leading a workshop at the upcoming Exosome Characterization & Analytical Development Summit.

March 1, 2024

·

4 min read

Pictured: a conceptual drawing of the small extrac

Drug Development

Exosome Therapeutics Are Paving a Path to Clinical Readiness

Exosomes show potential to treat myriad conditions, including cancer and inflammation, but experts are divided on whether the therapies are ready for the limelight.

March 4, 2024

·

6 min read

·

Sruthi S. Balakrishnan

ENT Devices Market Size, CAGR, Trends | Report 2022-2030

According to Vision Research Reports, the global ENT Devices market size is expected to be worth around US$ 32.05 billion by 2030.

July 7, 2022

·

9 min read

RION Releases Upgraded Digital Hearing Aid Series

August 21, 2006

·

1 min read